Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > hypoparathyroidism treatment market
Get a free sample of Hypoparathyroidism Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Hypoparathyroidism Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The hypoparathyroidism treatment industry is characterized by a dynamic interplay among pharmaceutical companies striving to capture a significant share. Companies such as Takeda Pharmaceutical Company Ltd., Ascendis Pharma, and F. Hoffman-La Roche Ltd. are notable players, with well-established product portfolios. These players are constantly involved in strategic alliances, collaborations, and market expansion initiatives to strengthen their foothold in the market.
Market players operating in the hypoparathyroidism treatment are as mentioned below:
Ascendis Pharma A/S, Amgen Inc., BioNTech SE, Bristol-Myers Squibb Company, Entera Bio Ltd., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., SK biopharmaceuticals Co., Ltd., Sun Pharmaceutical Industries Ltd. are some of the major industry contenders.
North America market for hypoparathyroidism treatment is expected to grow at 6.8% rate during 2024 and 2032, driven by the presence of advanced healthcare infrastructure with access to state-of-the-art medical facilities and specialized healthcare professionals.
The supplements segment garnered USD 888.2 million in 2023 and is set to gain traction by 2032, attributed to the well-established safety profile of supplements, and ease of availability.
The market size for hypoparathyroidism treatment was valued at USD 1.3 billion in 2023 and is estimated to account for USD 2.4 billion by 2032, driven by the increasing cases of hypo parathyroid disorders and rising number of thoracic surgeries.